CPRX News and Press, Catalyst Pharmaceuticals Inc. From 11/08/23

Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $(0.29) Diluted, Impacted by an $81.5 Million One Time Non-Recurring IPR&D Expense Related to the Acquisition of AGAMREE® License Third Quarter...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Catalyst Pharmaceuticals Inc. (CPRX) is expected to report $-0.24 for Q3 2023

CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, to...

2023-10-31 16:13:22 ET Summary Staring Catalyst Pharmaceuticals, Inc. coverage with a Buy rating with a 2-5-year target of $40 based on discounted cash flow valuation, offering 3x upside potential. The company has two FDA-approved products, Firdapse and Fycompa, with 92% annual re...

CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today a...

2023-10-26 16:34:53 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Call Transcript Catalyst gets FDA review for higher dose of Firdapse for rare ...

AGAMREE ® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy and Other Potential Indications Novel Cor...

CORAL GABLES, Fla., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that...

2023-10-19 08:43:04 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Call Transcript For further details see: Catalyst Pharmaceuticals appoints...